PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...
New NCCN guidelines recognize the utility of MammaPrint for guiding anthracycline therapy selection in HR+/HER2- early-stage ...
US biotech Gilead Sciences today announced that its Trodelvy (sacituzumab govitecan-hziy) has now been added to the National ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...
PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...
Invivyd, Inc. has announced that its investigational monoclonal antibody, PEMGARDA® (pemivibart), has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for ...
Panelists discuss how payer coverage restrictions often conflict with NCCN guidelines for BTK inhibitor therapies in CLL, impeding evidence-based care. Panelists discuss how payer coverage often ...
National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results